Clinical Trial Update: Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib for achieving minimal residual disease negativity in patients with chronic lymphocytic leukemia after frontline therapy; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Mayo Clinic | Conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2025-07-24